Use of Combination Immunotherapy Before Lung Cancer Surgery – The ASCO Post
Combination immunotherapy with the anti–PD-L1 monoclonal antibody durvalumab and other novel agents seemed to outperform durvalumab alone in the neoadjuvant setting for early-stage non–small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center, Hous ton. The findings, published in Cancer Discovery, 1 were first presented at the 2022 American Association for Cancer Research Annual Meeting. The multicenter, randomized phase II NeoCOAST clinical trial